Overview

  • Product nameAnti-KCNE1 antibody
    See all KCNE1 primary antibodies
  • Description
    Mouse monoclonal to KCNE1
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Recombinant Fragment
    Predicted to work with: Human
  • Immunogen

    Recombinant fragment: RSKKLEHSND PFNVYIESDA WQEKDKAYVQ ARVLESYRSC YVVENHLAIE QPNTHLPETK PSP, corresponding to amino acids 67-130 of Human KCNE1

Properties

Applications

Our Abpromise guarantee covers the use of ab55274 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 1-5 µg/ml.

    This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionAncillary protein that assembles as a beta subunit with a voltage-gated potassium channel complex of pore-forming alpha subunits. Modulates the gating kinetics and enhances stability of the channel complex. Assembled with KCNQ1/KVLQT1 is proposed to form the slowly activating delayed rectifier cardiac potassium (IKs) channel. The outward current reaches its steady state only after 50 seconds. Assembled with KCNH2/HERG may modulate the rapidly activating component of the delayed rectifying potassium current in heart (IKr).
    • Tissue specificityExpressed in heart, lung, kidney, testis, ovaries, small intestine, peripheral blood leukocytes. Not detected in pancreas, spleen, prostate and colon. Restrictively localized in the apical membrane portion of epithelial cells.
    • Involvement in diseaseJervell and Lange-Nielsen syndrome 2 (JLNS2) [MIM:612347]: An autosomal recessive disorder characterized by congenital deafness, prolongation of the QT interval, syncopal attacks due to ventricular arrhythmias, and a high risk of sudden death. Note=The disease is caused by mutations affecting the gene represented in this entry.
      Long QT syndrome 5 (LQT5) [MIM:613695]: A heart disorder characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to exercise or emotional stress, and can present with a sentinel event of sudden cardiac death in infancy. Note=The disease is caused by mutations affecting the gene represented in this entry.
    • Sequence similaritiesBelongs to the potassium channel KCNE family.
    • Post-translational
      modifications
      Phosphorylation inhibits the potassium current.
      N-glycosylation at Asn-26 occurs post-translationally, and requires prior cotranslational glycosylation at Asn-5.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • Delayed rectifier potassium channel subunit IsK antibody
      • Human cardiac delayed rectifier potassium channel protein antibody
      • IKs producing slow voltage gated potassium channel subunit beta Mink antibody
      • IKs producing slow voltage-gated potassium channel subunit beta Mink antibody
      • ISK antibody
      • JLNS 2 antibody
      • JLNS antibody
      • JLNS2 antibody
      • KCNE 1 antibody
      • KCNE1 antibody
      • KCNE1_HUMAN antibody
      • LQT 5 antibody
      • LQT5 antibody
      • MGC33114 antibody
      • Minimal potassium channel antibody
      • MinK antibody
      • Potassium voltage gated channel Isk related family member 1 antibody
      • Potassium voltage gated channel Isk related subfamily member 1 antibody
      • Potassium voltage gated channel subfamily E member 1 antibody
      • Potassium voltage-gated channel subfamily E member 1 antibody
      see all

    Anti-KCNE1 antibody images

    • Western blot against tagged recombinant protein immunogen using ab55274 KCNE1 antibody at 1ug/ml. Predicted band size of immunogen is 33 kDa.

      This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

    References for Anti-KCNE1 antibody (ab55274)

    This product has been referenced in:
    • Jia X  et al. MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model. PLoS One 8:e85639 (2013). WB . Read more (PubMed: 24386485) »

    See 1 Publication for this product

    Product Wall

    There are currently no Abreviews or Questions for ab55274.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"